Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

ÀڱðæºÎ¾Ï¿¡¼­ ¹æ»ç¼±Ä¡·á Áß Ç÷Áß Squamous Cell Carcinoma Antigen °ªÀÇ º¯È­ Serial Determinations of Serum Squamous Cell Carcinoma Antigen (SCC)during Radiotherapy for Uterine Cervix Cancer

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2001³â 19±Ç 2È£ p.136 ~ 141
À±Çü±Ù, ¹Ú¼®°Ç,
¼Ò¼Ó »ó¼¼Á¤º¸
À±Çü±Ù (  ) 
´Ü±¹´ëÇб³ Ä¡°ú´ëÇÐ ¼Ò¾ÆÄ¡°úÇб³½Ç

¹Ú¼®°Ç (  ) 
´Ü±¹´ëÇб³ ÀÇ°ú´ëÇÐ ÇÙÀÇÇб³½Ç

Abstract

¸ñÀû: ¹æ»ç¼±Ä¡·á Áß¿¡ Ç÷Áß Squamous Cell Carcionoma Antigen (SCC) °ªÀÇ º¯È­¸¦ °üÂûÇÏ¿© Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀÀ» °Ë»çÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀ» ¾Ë¾Æº¸°í ƯÈ÷ Ä¡·áÁß ¿ø°ÝÀüÀÌ µîÀ¸·Î ÀÎÇÑ Ä¡·á½ÇÆа¡ ¹ß»ýÇÒ °æ¿ì¿¡ Á¶±â¿¡ ¹ß°ßÇÒ ¼ö ÀÖ´ÂÁö ¾Ë¾Æº¸±â À§Çؼ­ º» ¿¬±¸¸¦
½ÃÇàÇÏ¿´´Ù.
´ë»ó ¹× ¹æ¹ý: 1998³â 12¿ùºÎÅÍ 1999³â 8¿ù±îÁö ´Ü±¹´ëÇк´¿ø Ä¡·á¹æ»ç¼±°ú¿¡¼­ ¿ø¹ß¼º ÀÚ
±Ã°æºÎ¾ÏÀ¸·Î ±ÙÄ¡Àû ¹æ»ç¼±Ä¡·á¸¦ ½ÃÇà ¹ÞÀº ȯÀÚ Áß 13·Ê¸¦ ´ë»óÀ¸·Î ÇÏ¿´°í Ä¡·áÀü ¹×
¿ÜºÎÁ¶»ç ¹æ»ç¼±Ä¡·á Áß ¸ÅÁÖ 1ȸ¾¿, ±×¸®°í Ä¡·á ÈÄ ¿¡ Ç÷Áß SCC Ä¡¸¦ ÃøÁ¤, ºÐ¼®ÇÏ¿´´Ù.
°á°ú: 13·Ê Áß 9·Ê¿¡¼­´Â ¿ÜºÎÁ¶»ç ¹æ»ç¼±Ä¡·á Á¾·á ÈÄ¿¡ ½ÃÇàÇÑ °Ë»ç»ó ¿ø°ÝÀüÀÌÀÇ ¼Ò°ßÀÌ
¾ø¾î¼­ Àڱð­³» ±ÙÁ¢¹æ»ç¼±Ä¡·á¸¦ ½ÃÇàÇÒ ¼ö ÀÖ¾ú´Ù À̵é 9·Ê Áß 7·Ê´Â ¹æ»ç¼±Ä¡·á Àü¿¡
Ç÷Áß SCC Ä¡°¡ »ó½ÂµÇ¾î ÀÖ¾ú´Ù. ÀÌ 7·ÊÁß 6·Ê¿¡¼­ Ä¡·á ÈÄ ¿ÏÀü °üÇØÀÇ ¼Ò°ßÀ» º¸¿´´Âµ¥
±×Áß 5·Ê¿¡¼­´Â Ç÷Áß SCC Ä¡°¡ Á¤»óÈ­µÇ¾ú´Ù. ºÎºÐ°üÇظ¦ º¸ÀÎ 1·Ê¿¡¼­´Â Ç÷Áß SCCÄ¡°¡
Ä¡·áÀüº¸´Ù ³·¾ÆÁ³À¸³ª Á¤»ó¹üÀ§º¸´Ù´Â ³ô¾Ò´Ù. 13·Ê Áß ³ª¸ÓÁö 4·Ê¿¡¼­´Â ¿ÜºÎÁ¶»ç ¹æ»ç¼±
Ä¡·á Á¾·á½ÃÁ¡¿¡ ¿ø°ÝÀüÀÌ°¡ È®ÀεǾ Àڱð­³» ±ÙÁ¢¹æ»ç¼±Ä¡·á¸¦ ½ÃÇàÇÏÁö ¸øÇÏ¿´´Ù. ÀÌ
Áß 3·Ê´Â ¹æ»ç¼± Ä¡·á Àü¿¡ Ç÷Áß SCC Ä¡°¡ »ó½ÂµÇ¾î ÀÖ¾ú´Âµ¥ ¿ÜºÎÁ¶»ç ¹æ»ç¼±Ä¡·á Á¾·á
Á÷ÈÄ ½ÃÇàÇÑ ÈäºÎ´Ü¼øÈ°¿µ »çÁø»ó ¿ø°ÝÀüÀÌÀÇ ¼Ò°ßÀÌ ³ªÅ¸³µÀ½¿¡µµ ºÒ±¸ÇÏ°í ÀÌ ¶§ÀÇ Ç÷Áß
SCC Ä¡´Â °¨¼ÒÇÏ¿´´Ù. Ä¡·á Àü¿¡ Ç÷Áß SCC°¡ »ó½ÂµÇ¾î ÀÖ¾ú´ø 10·Ê Áß 7·Ê¿¡¼­ 9 Gy Ä¡
·á ÈÄ¿¡ Ç÷Áß SCC °ªÀÌ ´õ¿í Áõ°¡ÇÏ¿´À¸¸ç Åë°èÀûÀ¸·Î À¯ÀÇÇÑ Áõ°¡¿´´Ù. 18 Gy ½ÃÇàÇÑ ÈÄ
ÀÇ °ªÀº 9 Gy ½ÃÇàÇÑ °æ¿ì¿¡ ºñÇؼ­´Â 3·Ê¿¡¼­ Áõ°¡ÇÏ¿´°í 7¿¹¿¡¼­ °¨¼ÒÇÏ¿´À¸¸ç Ä¡·á Àü
¿¡ ºñÇؼ­´Â 4·Ê¿¡¼­ Áõ°¡ÇÏ¿´°í 6·Ê¿¡¼­ °¨¼ÒÇÏ¿´´Ù. 18Gy ÀÌÈÄ¿¡´Â ¹æ»ç¼±·®ÀÇ Áõ°¡¿¡
µû¶ó¼­ °è¼ÓÀûÀ¸·Î Ç÷Áß SCC Ä¡°¡ °¨¼ÒÇÏ¿© Á¾¾çÀÌ ¿ÏÀü °üÇØ¿¡ À̸£¸é Á¤»ó¹üÀ§¿¡ µµ´Þ
ÇÏ¿´´Ù.
°á·Ð: ¹æ»ç¼±Ä¡·á Áß¿¡ Ç÷Áß SCC Ä¡´Â 9Gy±îÁö´Â Ä¡·á Àü¿¡ ºñÇؼ­ ÀϽÃÀûÀ¸·Î Áõ°¡ÇÏ°í
18 Gy¿¡¼­´Â Ä¡·áÀüÀÇ °ª°ú ºñ½ÁÇØÁö¸ç ±× ÈÄ¿¡´Â ºü¸£°Ô °¨¼ÒÇؼ­ Á¾¾çÀÌ ¿ÏÀü °üÇØ¿¡ ÀÌ
¸£¸é Á¤»óÄ¡¿¡ µµ´ÞÇÏ¿´´Ù. ¿ÜºÎÁ¶»ç ¹æ»ç¼±Ä¡·á Á¾·á ÈÄ ÈäºÎ´Ü¼øÃÔ¿µ »çÁø»ó Æó ÀüÀÌÀÇ
¼Ò°ßÀ» º¸ÀÎ °æ¿ìµéµµ Ç÷Áß SCC Ä¡´Â ÁÖ·Î ÀڱðæºÎÀÇ ÁÖÁ¾¾çÀÇ °üÇصµ¿¡ µû¶ó °¨¼ÒÇÏ¿©
ÁÖÁ¾¾çÀÇ ¿ÏÀü°üÇؽà Á¤»óÈ­µÇ¾ú°í Æó ÀüÀÌÀÇ ¹ßÇö¿¡µµ ºÒ±¸ÇÏ°í Áõ°¡ÇÏÁö ¾Ê¾Ò´Ù.

Purpose: To evaluate the significance of serum SCC for the monitoring of treatment response and the early detection of distant metastasis during radiotherapy (RT).
Materials and Methods: In 13 patients with histologically proven primary squamous cell
carcinoma of ulterine cervix, serum SCC values were checked in pre-RT point, weekly
during RT, and in post-RT point
Results: In 4 of 13 cases, metastasis appeared at the end of external RT, so that
intracavitary radiation couldn't be performed. Of these 4 cases 3 with elevated pre-RT
SCC level, who resulted in lung metastasis on chest PA at the end of external RT
showed decreased post-RT SCC value despite of metastasis. Of all 10 cases with
elevated pre-RT SCC value (including 3 with metastasis at the end of external RT),
SCC value was higher than pre-RT value in 7 at 9 Gy and the difference was
statistically significant. At 18 Gy, SCC was higher in 4 and lower in 6 than pre-RT
value. After 18 Gy, SCC value decreased continuously to the end of RT in all 10 cases.
Conclusion: During RT, SCC value increased initially at 9 Gy. To 18 Gy, SCC value
decreased to the nearly same with pre-RT value. After 18 Gy, to the end of RT, SCC
value decreased continuously and normalized in completely responded cases. In cases
with appearance of lung metastasis, SCC value also decreased with the disappearance of
main mass of uterine cervix despite of metastasis.

Å°¿öµå

ÀڱðæºÎ¾Ï; ¹æ»ç¼±Ä¡·á; SCC Ag; Uterine cervical cancer; SCC Ag; Radiotherapy;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS